Loading…
Jyong Biotech Ltd. is projected to rise to $2.57 by 2027, a +20% move from its current price of $2.15. MENS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.06 | $2.15 | $2.25 | +0.01% |
| Aug 5 | $2.02 | $2.15 | $2.29 | +0.02% |
| Aug 6 | $1.99 | $2.15 | $2.32 | +0.03% |
| Aug 7 | $1.97 | $2.15 | $2.35 | +0.04% |
| Aug 8 | $1.95 | $2.15 | $2.37 | +0.05% |
| Aug 9 | $1.93 | $2.15 | $2.40 | +0.07% |
| Aug 10 | $1.91 | $2.15 | $2.42 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.91 | $2.15 | $2.42 | +0.08% |
| Week 2 | $1.82 | $2.15 | $2.54 | +0.15% |
| Week 3 | $1.76 | $2.15 | $2.64 | +0.23% |
| Week 4 | $1.71 | $2.16 | $2.73 | +0.31% |
| Week 5 | $1.66 | $2.16 | $2.80 | +0.38% |
| Week 6 | $1.62 | $2.16 | $2.88 | +0.46% |
| Week 7 | $1.59 | $2.16 | $2.95 | +0.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jyong Biotech Ltd. is a science-driven biotechnology company that engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Jyong Biotech Ltd. trades under the symbol MENS and has a current price of $2.15. Its market capitalization is $163.46M, and it is ranked 3889 by market cap. This places the stock among smaller-cap biotech listings with a focus on urinary system diseases.
The longer-run price outlook is notably bullish in the later forecast years, with substantial projected gains and high upside potential.
A major floor 54.0% below — a decisive break under it would weaken the trend.
The nearest floor, 27.4% below — buyers have tended to step in here.
The nearest ceiling, 26.0% above — a clean break opens room to run.
A major ceiling 53.0% above — clearing it would confirm fresh momentum.
Key MENS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MENS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.29 | Sell | $2.27 | Sell |
| MA 10 | $2.41 | Sell | $2.32 | Sell |
| MA 20 | $2.32 | Sell | $2.28 | Sell |
| MA 50 | $2.09 | Buy | $2.25 | Sell |
| MA 100 | $2.14 | Buy | $3.72 | Sell |
| MA 200 | $10.60 | Sell | $8.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -94.68 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -6.11 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.78 | Buy |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 32.71 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 2.15 | Sell |
| ADX (14) | 19.71 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is neutral overall. RSI14 stands at 50, with a near-term trading context that includes SMA50 at $2.09 and SMA200 at $10.60. The near-term price should be viewed within a framework of a wider long-term baseline, rather than as a driver of immediate momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.46 | $2.15 | $2.95 | 0% | Neutral | |
| $1.87 | $2.57 | $3.83 | +20% | Neutral | |
| $2.50 | $3.66 | $5.83 | +70% | Bullish | |
| $2.56 | $3.96 | $6.62 | +84% | Bullish | |
| $2.59 | $4.21 | $7.34 | +96% | Bullish | |
| $2.85 | $4.86 | $8.77 | +126% | Bullish | |
| $2.39 | $4.25 | $7.92 | +98% | Bullish | |
| $2.46 | $4.56 | $8.74 | +112% | Bullish | |
| $3.20 | $6.18 | $12.15 | +188% | Bullish | |
| $3.53 | $7.09 | $14.26 | +230% | Bullish | |
| $3.92 | $8.71 | $19.27 | +305% | Bullish | |
| $9.22 | $20.49 | $47.13 | +853% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.46 | $2.15 | $2.54 | +0.00% |
| September 2026 | $1.66 | $2.02 | $2.57 | -5.89% |
| October 2026 | $1.76 | $2.17 | $2.82 | +7.32% |
| November 2026 | $1.79 | $2.24 | $2.95 | +3.13% |
| December 2026 | $1.75 | $2.20 | $2.95 | -1.54% |
Click any year to see its month-by-month MENS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MENS is projected to trade between $1.46 and $2.95, averaging $2.15 — a potential gain of 0% from today's $2.15. Price action looks broadly range-bound.
Jyong Biotech Ltd.'s 2027 outlook centres on $2.57, within a $1.87 to $3.83 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, MENS could reach as high as $5.83, with a base case around $3.66 and support toward $2.50 — roughly +70% from $2.15. Momentum favours further upside here.
Expect MENS to range from $2.56 to $6.62 through 2029. The $3.96 average target implies a +84% move from current prices. That is up +8% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MENS price prediction for 2030 points to an average of $4.21 (low $2.59, high $7.34) — a potential gain of +96% on today's $2.15. Momentum favours further upside here.
In 2031, MENS is projected to trade between $2.85 and $8.77, averaging $4.86 — a potential gain of +126% from today's $2.15. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Jyong Biotech Ltd.'s 2032 outlook centres on $4.25, within a $2.39 to $7.92 range. That is -12% versus the projected 2031 average. That marks a +98% change versus current levels. Momentum favours further upside here.
By 2033, MENS could reach as high as $8.74, with a base case around $4.56 and support toward $2.46 — roughly +112% from $2.15. Buyers look set to stay in control over this stretch.
Expect MENS to range from $3.20 to $12.15 through 2034. The $6.18 average target implies a +188% move from current prices. That is up +36% on the projected 2033 average. Momentum favours further upside here.
The MENS price prediction for 2035 points to an average of $7.09 (low $3.53, high $14.26) — a potential gain of +230% on today's $2.15. Buyers look set to stay in control over this stretch.
In 2040, MENS is projected to trade between $3.92 and $19.27, averaging $8.71 — a potential gain of +305% from today's $2.15. That is up +23% on the projected 2035 average. Momentum favours further upside here.
Jyong Biotech Ltd.'s 2050 outlook centres on $20.49, within a $9.22 to $47.13 range. That is up +135% on the projected 2040 average. That marks a +853% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MENS today (≈ 465.116279 MENS) could be worth
$9,530.83
+$8,530.83 (+853%) by 2050 · US Dollar
Based on the average projected MENS price of $20.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MENSwould be worth at today's price.
$1,000 invested in MENS on Jul 31, 2025 (≈ 52.465899 MENS) would be worth
$112.8
-$887.2 (-88.7%) today · 0.11× · US Dollar
Based on a MENS entry price of $19.06 vs. today's $2.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.36 | $911.02 | -8.9% |
| 1 month ago | $2.05 | $1,048.78 | +4.9% |
| 3 months ago | $2.25 | $955.56 | -4.4% |
| 6 months ago | $2.4 | $895.83 | -10.4% |
| 1 year ago | $19.06 | $112.8 | -88.7% |
| All time (1.1y) ago | $10.11 | $212.66 | -78.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MENS forecast.
Our base-case forecast reaches $4.30 around 2031.
Implied market cap at $4.30: $319.2M
The year-by-year forecast shows a gradual rise in expected value from 2026 through 2050. In 2026 the average price is $2.15 with a min of $1.46 and a max of $2.95 (ROI 0, sentiment NEUTRAL). By 2030 the average is $4.22 with a min of $2.60 and a max of $7.36 (ROI 96.4, sentiment BULLISH).
The outlook then continues higher, with 2040 averaging $8.70 (min $3.91, max $19.25, ROI 304.6) and 2050 averaging $20.50 (min $9.23, max $47.15, ROI 853.5). Across these years, sentiment shifts to BULLISH from 2028 onward, reflecting stronger upside expectations despite inherent volatility (annualized volatility of 80%). These are estimates, not guarantees, and should be weighed against risk and individual circumstances.
Tap a question to reveal the answer.
Avg $4.22, min $2.60, max $7.36, ROI 96.4%, sentiment BULLISH.
The forecast shows a bullish trajectory from 2028 onward, with Avg rising to $4.22 by 2030 and to $20.50 by 2050, and ROI reaching 96.4% in 2030 and 853.5% by 2050, though early years (2026) show neutral sentiment and 80% volatility indicates substantial risk.
Current price is $2.15 and market cap is $163.46M.
Bullish sentiment is indicated starting in 2028, with continued bullish outlook through 2050 (e.g., 2028 avg $3.66, 2050 avg $20.50).
RSI14 is 50; SMA50 is $2.09; SMA200 is $10.60; 30-day range is $1.61 to $2.88; near-term support is $1.56 and resistance is $2.71.
Jyong Biotech Ltd. Community Discussion
0Share your Jyong Biotech Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.